Latest in Cardiology from ACC.org

• New ACC Scientific Statement Details Role of Inflammation in CVD
  A new ACC Scientific Statement on Inflammation and Cardiovascular Disease (CVD) highlights new groundbreaking research linking inflammation atherosclerotic cardiovascular disease (ASCVD) and provides consensus-based recommendations for evaluation, treatment and prevention reflecting this new era.
• ACC CardioSurve: Improved Education, Guidelines For Clinicians Could Boost Cardiogenetic Testing
  Cardiogenetic testing could be more widely implemented if clinicians had improved access to genetic counselors and professionals, clearer guidelines and expanded education, according to a survey of the ACC CardioSurve Panel and published July 7 in JACC: Advances.
• FDA Update: Agency Approves Evinacumab-dgnb ANGPTL3 Antibody For Children With HoFH
  The U.S. Food and Drug Administration (FDA) has approved evinacumab-dgnb ANGPTL3 antibody (Evkeeza®) to treat homozygous familial hypercholesterolemia (HoFH) in children as young as 1-year-old, according to a Regeneron® press release.
• ACC Practice Made Perfect: Acing the Transition: From FIT to Faculty
  In this episode, Drs. Laura Onderko, Aditya Bharadwaj, and David Winchester explore the transition from fellowship to faculty.
• ACC CardiaCast: GDMT Will Not Delay HF Treatment
  In this episode, Michelle M. Kittleson, MD, PhD, FACC, and Estefania Oliveros Soles, MD, MSc, FACC discuss challenges in heart failure (HF) care, focusing on utilization of guideline-directed medical therapy (GDMT). Learners will hear tips on how to add and maximize GDMT in patients with HF.